[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2002243778A1 - Treatment of ppar mediated diseases - Google Patents

Treatment of ppar mediated diseases

Info

Publication number
AU2002243778A1
AU2002243778A1 AU2002243778A AU2002243778A AU2002243778A1 AU 2002243778 A1 AU2002243778 A1 AU 2002243778A1 AU 2002243778 A AU2002243778 A AU 2002243778A AU 2002243778 A AU2002243778 A AU 2002243778A AU 2002243778 A1 AU2002243778 A1 AU 2002243778A1
Authority
AU
Australia
Prior art keywords
treatment
mediated diseases
ppar mediated
ppar
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002243778A
Inventor
Timothy Mark Willson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU2002243778A1 publication Critical patent/AU2002243778A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1783—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Food Science & Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
AU2002243778A 2001-02-02 2002-01-31 Treatment of ppar mediated diseases Abandoned AU2002243778A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26639301P 2001-02-02 2001-02-02
US60/266,393 2001-02-02
PCT/US2002/003017 WO2002070011A2 (en) 2001-02-02 2002-01-31 Treatment of ppar mediated diseases

Publications (1)

Publication Number Publication Date
AU2002243778A1 true AU2002243778A1 (en) 2002-09-19

Family

ID=23014384

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002243778A Abandoned AU2002243778A1 (en) 2001-02-02 2002-01-31 Treatment of ppar mediated diseases

Country Status (3)

Country Link
EP (1) EP1357914A2 (en)
AU (1) AU2002243778A1 (en)
WO (1) WO2002070011A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1585638A (en) 2001-09-14 2005-02-23 图拉里克公司 Linked biaryl compounds
KR100474202B1 (en) * 2002-05-04 2005-03-08 강헌중 Process for preparing thiazol derivative and the intermediate compounds for preparing the same
ATE486055T1 (en) 2004-05-05 2010-11-15 High Point Pharmaceuticals Llc NEW COMPOUNDS, THEIR PRODUCTION AND USE
EP1745014B1 (en) 2004-05-05 2011-07-06 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
WO2007003581A1 (en) 2005-06-30 2007-01-11 Novo Nordisk A/S Phenoxy acetic acids as ppar delta activators
NZ568488A (en) 2005-12-22 2011-07-29 High Point Pharmaceuticals Llc Phenoxy acetic acids as PPAR delta activators
US7943612B2 (en) 2006-03-09 2011-05-17 High Point Pharmaceuticals, Llc Compounds that modulate PPAR activity, their preparation and use
EP3756661A1 (en) 2013-09-09 2020-12-30 vTv Therapeutics LLC Use of a ppar-delta agonist for treating muscle atrophy
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028149A1 (en) * 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
AU6773598A (en) * 1997-03-26 1998-10-20 Institut Pasteur Treatment of gastrointestinal disease with ppar modulators
WO1999004815A1 (en) * 1997-07-24 1999-02-04 Yamanouchi Pharmaceutical Co., Ltd. Medicinal compositions with cholesterol-lowering effect
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
GB9917405D0 (en) * 1999-07-23 1999-09-22 Univ Dundee Methods of treatment and drug screening methods
PL356745A1 (en) * 1999-11-10 2004-06-28 Takeda Chemical Industries, Ltd Body weight gain inhibitors
KR20020081424A (en) * 2000-03-09 2002-10-26 아벤티스 파마 도이칠란트 게엠베하 Therapeutic uses of PPAR mediators
JP2001354671A (en) * 2000-04-14 2001-12-25 Nippon Chemiphar Co Ltd ACTIVATOR FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR delta
CA2417005A1 (en) * 2000-07-20 2002-01-31 Bristol Myers Squibb Company Regulators of ppar.delta.(.beta.) and their use in the treatment of obesity and insulin resistance
ATE542805T1 (en) * 2000-08-11 2012-02-15 Nippon Chemiphar Co PPAR-DELTA ACTIVATORS
GB0024361D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
JPWO2002046154A1 (en) * 2000-12-05 2004-04-08 日本ケミファ株式会社 Activator of peroxisome proliferator-activated receptor δ

Also Published As

Publication number Publication date
WO2002070011A2 (en) 2002-09-12
EP1357914A2 (en) 2003-11-05
WO2002070011A3 (en) 2003-04-24

Similar Documents

Publication Publication Date Title
AU2002332430A1 (en) Methods of treating neuropilin-mediated diseases
AU2002257936A1 (en) Methods of well treatment
AU2002329570A1 (en) Method of monitoring neuroprotective treatment
AU2002210385A1 (en) Furazanyl-triazole derivates for the treatment of diseases
AU2002360555A1 (en) Treatment of genitourinary tract disorders
AU2002243778A1 (en) Treatment of ppar mediated diseases
AU2002319286A1 (en) Skin treatment
AU2003259833A1 (en) Methods of treating neurodegenerative diseases
AU2003270540A1 (en) Treatment of cyclooxygenase-3 mediated diseases and disorders
AU2003213898A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU2002311845A1 (en) Methods of treating intestinal inflammation
AU1405001A (en) Treatment of diseases
AUPR731901A0 (en) Method of treatment
AU2002359310A1 (en) Treating diseases mediated by metalloprotease-shed proteins
GB0100092D0 (en) Treatment of degenerative diseases
AU2001253560A1 (en) Methods of treatment
AU2003297570A1 (en) Treatment of skin diseases
AU2002365654A1 (en) Treatment of diseases via the skin
AU2002247179A1 (en) Treatment of hpv caused diseases
AU2003208809A1 (en) Treatment of neuroblastoma
AU2002362224A1 (en) Methods of treating cytokine mediated diseases
AU2003269254A1 (en) Treatment of vascular diseases
AU2002254030A1 (en) Treatment of schizophrenia
AU2002343689A1 (en) Methods for treatment of inflammatory diseases
AU2003272553A1 (en) Treatment of schizophrenia

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase